G1 Therapeutics, Inc.
Combination therapy for treatment of cancer

Last updated:

Abstract:

Compositions, combinations and methods comprising a CDK4/6 inhibitor of Formula D with a selective estrogen receptor downregulator of Formula A, B or C that are advantageous for the treatment of abnormal cellular proliferation, including a cancer or a tumor.

Status:
Grant
Type:

Utility

Filling date:

2 Jul 2019

Issue date:

21 Jun 2022